Skip to main content
Top
Published in: Supportive Care in Cancer 11/2007

01-11-2007 | Short Communiation

Adjunct dipyrone in association with oral morphine for cancer-related pain: the sooner the better

Authors: José F. Duarte Souza, Paula P. Lajolo, Hélio Pinczowski, Auro del Giglio

Published in: Supportive Care in Cancer | Issue 11/2007

Login to get access

Abstract

Introduction

Adjunct nonopioid analgesics may improve pain control in patients with cancer needing morphine or its derivates. Dypirone is a cheap nonopioid analgesic widely used in many countries.

Objective

The objective of the study was to evaluate, whenever morphine was started, if associating dipyrone with it would improve pain control and if this effect was time dependent.

Materials and methods

This is a double-blind placebo-controlled randomized crossover study. Thirty-four ambulatory cancer patients experiencing cancer-related pain for which oral morphine was to be started at the dose of 10 mg orally (PO) every 4 h were randomized to take either dipyrone 500 mg PO every 6 h or placebo. After 48 h, patients would be switched from dipyrone to placebo and vice versa. Pain was the primary outcome and was measured using a visual analogue scale before starting medications, at 48 and 96 h.

Results

We randomized 16 patients to start with placebo (group 1) and 18 with dipyrone (group 2). Pain scores for groups 1 and 2 were at baseline: 7.31 ± 0.29 vs 6.88 ± 0.28 (p = 0.3), at 48 h: 7.06 ± 0.32 vs 5.5 ± 0.31 (p = 0.001), and at 96 h: 3.18 ± 0.39 vs 1.94 ± 0.37 (p = 0.03). Both groups had significant improvements in pain scores after introducing dipyrone (p < 0.001, for both). Main toxicities were nausea, vomiting, epigastric pain, and myalgias. Twenty-eight patients chose dipyrone, four placebo, and two were indifferent.

Conclusions

We conclude that dipyrone adds significantly to the analgesic effect of morphine and, when given at the time of starting morphine, results in better pain scores even after dipyrone is discontinued.
Literature
1.
go back to reference Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA et al (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19):1407–1427, Oct 5PubMedCrossRef Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA et al (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19):1407–1427, Oct 5PubMedCrossRef
2.
go back to reference Fallon M, Hanks G, Cherny N (2006) Principles of control of cancer pain. BMJ 332(7548):1022–1024, Apr 29PubMedCrossRef Fallon M, Hanks G, Cherny N (2006) Principles of control of cancer pain. BMJ 332(7548):1022–1024, Apr 29PubMedCrossRef
3.
go back to reference Volz M, Kellner HM (1980) Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br J Clin Pharmacol 10(Suppl 2):299S–308S, OctPubMed Volz M, Kellner HM (1980) Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br J Clin Pharmacol 10(Suppl 2):299S–308S, OctPubMed
4.
go back to reference Edwards JE, Meseguer F, Faura CC, Moore RA, McQuay HJ (2001) Single-dose dipyrone for acute postoperative pain. Cochrane Database Syst Rev 3:CD003227PubMed Edwards JE, Meseguer F, Faura CC, Moore RA, McQuay HJ (2001) Single-dose dipyrone for acute postoperative pain. Cochrane Database Syst Rev 3:CD003227PubMed
5.
go back to reference Shinar E, Hershko C (1983) Causes of agranulocytosis in a hospital population: identification of dipyrone as an important causative agent. Isr J Med Sci 19(3):225–229 MarPubMed Shinar E, Hershko C (1983) Causes of agranulocytosis in a hospital population: identification of dipyrone as an important causative agent. Isr J Med Sci 19(3):225–229 MarPubMed
6.
go back to reference Heit WF (1983) Hematologic effects of antipyretic analgesics. Drug-induced agranulocytosis. Am J Med 75(5A):65–69, Nov 14PubMedCrossRef Heit WF (1983) Hematologic effects of antipyretic analgesics. Drug-induced agranulocytosis. Am J Med 75(5A):65–69, Nov 14PubMedCrossRef
7.
go back to reference Hamerschlak N, Cavalcanti AB (2005) Neutropenia, agranulocytosis and dipyrone. Sao Paulo Med J 123(5):247–249, Sep 1PubMedCrossRef Hamerschlak N, Cavalcanti AB (2005) Neutropenia, agranulocytosis and dipyrone. Sao Paulo Med J 123(5):247–249, Sep 1PubMedCrossRef
8.
go back to reference Backstrom M, Hagg S, Mjorndal T, Dahlqvist R (2002) Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis. Pharmacoepidemiol Drug Saf 11(3):239–245, AprPubMedCrossRef Backstrom M, Hagg S, Mjorndal T, Dahlqvist R (2002) Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis. Pharmacoepidemiol Drug Saf 11(3):239–245, AprPubMedCrossRef
9.
go back to reference Ibanez L, Vidal X, Ballarin E, Laporte JR (2005) Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol 60(11):821–829, JanPubMedCrossRef Ibanez L, Vidal X, Ballarin E, Laporte JR (2005) Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol 60(11):821–829, JanPubMedCrossRef
10.
go back to reference Laporte JR, Carne X, Vidal X, Moreno V, Juan J (1991) Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet 337(8733):85–89, Jan 12PubMedCrossRef Laporte JR, Carne X, Vidal X, Moreno V, Juan J (1991) Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet 337(8733):85–89, Jan 12PubMedCrossRef
11.
go back to reference Stockler M, Vardy J, Pillai A, Warr D ( 2004) Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 22(16):3389–3394, Aug 15PubMedCrossRef Stockler M, Vardy J, Pillai A, Warr D ( 2004) Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 22(16):3389–3394, Aug 15PubMedCrossRef
12.
go back to reference Kampe S, Warm M, Landwehr S, Dagtekin O, Haussmann S, Paul M et al (2006) Clinical equivalence of IV paracetamol compared to IV dipyrone for postoperative analgesia after surgery for breast cancer. Curr Med Res Opin 22(10):1949–1954, OctPubMedCrossRef Kampe S, Warm M, Landwehr S, Dagtekin O, Haussmann S, Paul M et al (2006) Clinical equivalence of IV paracetamol compared to IV dipyrone for postoperative analgesia after surgery for breast cancer. Curr Med Res Opin 22(10):1949–1954, OctPubMedCrossRef
13.
go back to reference Rodriguez M, Barutell C, Rull M, Galvez R, Pallares J, Vidal F et al (1994) Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. Eur J Cancer 30A(5):584–587PubMedCrossRef Rodriguez M, Barutell C, Rull M, Galvez R, Pallares J, Vidal F et al (1994) Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. Eur J Cancer 30A(5):584–587PubMedCrossRef
Metadata
Title
Adjunct dipyrone in association with oral morphine for cancer-related pain: the sooner the better
Authors
José F. Duarte Souza
Paula P. Lajolo
Hélio Pinczowski
Auro del Giglio
Publication date
01-11-2007
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 11/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0327-7

Other articles of this Issue 11/2007

Supportive Care in Cancer 11/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine